Ex26
SIGMA/SML1680 - ≥98% (HPLC)
Synonym: 1-[[[5′-[[1-(4-Chloro-3-methylphenyl)ethyl]amino]-2′-fluoro-3,5-dimethyl[1,1′-biphenyl]-4-yl]carbonyl]amino]-cyclopropanecarboxylic acid
CAS Number: 1233332-37-0
Empirical Formula (Hill Notation): C28H28ClFN2O3
Molecular Weight: 494.98
Linear Formula: C28H28ClFN2O3
Product Type: Chemical
assay | ≥98% (HPLC) |
color | white to beige |
form | powder |
Quality Level | 100 ![]() |
SMILES string | ClC1=CC=C(C(C)NC2=CC=C(F) |
solubility | DMSO: 25 mg/mL, clear |
storage temp. | 2-8°C |
Biochem/physiol Actions: | Ex26 is a peripherally-restricted biphenylcarboxamide derivative that acts as a highly potent and subtype-selective S1P1 antagonist (IC50 = 0.93 nM against S1PR1 and >3.1 μM against S1PR2/3/4/5). Ex26 significantly elevates CpG-A-stimulated interferon (IFN) production in plasmacytoid dendritic cell culture (10 μM) and prevents S1P1 agonist-induced S1P1 receptor internalization and polyubiquitinylation in HEK cells (0.1-1,000 nM). Ex26 induces lymphocyte sequestration (ED50 = 0.06 mg/kg, i.p.) in lymph nodes and pulmonary edema (2 hr post 30 mg/kg i.p.) in mice, leading to the inhibition of lymphocyte and thymocyte egress (0.1 mg/kg/hr continuously for 3 days after a loading dose of 3 mg/kg). Ex26 has been shown to ameliorate experimental autoimmune encephalomyelitis (EAE) in a mouse MS model and elevate CpG-A-stimulated serum IFN upregulation in mice in vivo (30 mg/kg/d, i.p.). |
Packaging: | 5, 25 mg in glass bottle |
Hazard statements | H413 |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Purity | ≥98% (HPLC) |
Storage Temp. | 2-8°C |
UNSPSC | 12352200 |